GLPG Research and Charts

GLPG - Galapagos NV ADR (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-06-30)

Last 27.99	Change ⇑ +0.01 (+0.04%)	Volume 133,978
	Open 27.83	High 28.09	Low 27.75

8EMA (Daily) 27.92	40EMA (Daily) 27.66	50EMA (Daily) 27.47	STO (Daily) 47.444	MACD Hist (Daily) -0.165
8EMA (Weekly) 27.738	40EMA (Weekly) 27.25	50EMA (Weekly) 27.68	STO (Weekly) 78.171	MACD Hist (Weekly) 0.505


Company Profile
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.